Table 1.
Demographic and baseline characteristics
| Characteristics | Patients (n = 45) |
|---|---|
| Mean age, year (s.d.) | 57.3 (7.9) |
| Race, n (%) | |
| White | 42 (93.3) |
| Black/African American | 3 (6.7) |
| Treatment received during the clinical study, n (%) | |
| CCH | 33 (73.3) |
| Placebo | 12 (26.7) |
| History of ED, n (%) | 22 (48.9) |
| Mean time since PD diagnosis, year (s.d.) | 2.8 (2.5) |
| Duration of penile pain, n (%) | |
| No pain | 34 (75.6) |
| <3 months | 0 |
| 3–6 months | 1 (2.2) |
| 6–9 months | 1 (2.2) |
| >9 months | 9 (20.0) |
| Time between first notice of penile changes and study entry | |
| 6 months–1 year | 2 (4.4) |
| 1–2 years | 13 (28.9) |
| 2–5 years | 17 (37.8) |
| >5 years | 12 (26.7) |
| Not reported | 1 (2.2) |
| Other medications used for PD, n (%) | |
| None | 17 (37.8) |
| Oral medications/vitamins | 23 (51.1) |
| Creams/topical ointments | 10 (22.2) |
| Stretching/vacuum devices | 6 (13.3) |
| Injections | 5 (11.1) |
| Treatment during phase 2b trial, n (%) | |
| CCH group | n = 33 |
| Week 36 GAPDQ respondera | 20 (60.6) |
| Week 36 GAPDQ nonresponder | 11 (33.3) |
| Not evaluableb | 2 (6.1) |
| Placebo group | n = 12 |
| Week 36 GAPDQ respondera | 4 (33.3) |
| Week 36 GAPDQ nonresponder | 6 (50.0) |
| Not evaluableb | 2 (16.7) |
CCH collagenase clostridium histolyticum, ED erectile dysfunction, GAPDQ Global Assessment of the Peyronie’s Disease Questionnaire, PD Peyronie’s disease, s.d. standard deviation
aGAPDQ responders had GAPDQ question 5 score ≥ 1 at posttreatment week 36
bNo GAPDQ assessment at posttreatment week 36